Founded in 1986 by Mr. P.V. Ramaprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly active and talented medical professionals, Aurobindo Pharma was started out off a vision, A vision that promise to touch million lives through their large scale of operation.
The company began its operations in 1988-89 with only a single unit manufacturing Semi-Synthetic Penicillin (SSP) at Pondicherry, India. Aurobindo Pharma went public in 1992 and listed its shares in the Indian stock exchanges in 1995.
In addition to being the market leader in Semi-Synthetic Penicillins, it has a strong foothold in key therapeutic categories such as neurosciences, cardiovascular, anti-retrovirals, anti-diabetics, gastroenterology and cephalosporins, etc..
Through cost effective manufacturing capabilities, large scale operation, strategic alignment with its core business focus and a few loyal customers, the company entered the high margin specialty generic formulations segment. It is R&D focused, Innovation centred . vision driven and has a multi-product portfolio with multiple manufacturing facilities in several countries across the breath of the globe. It aims to achieve USD 2 billion revenues by 2015-16. Aurobindo Pharma exports its formulations to more than 125 countries across the world with more than 70% of its revenues generated out of off-shore operations.
Its’ best known brands are Aurox, Cedbrox, Tripcut, Cefactam, ProxtL, AxtL, Recipro, Diceta etc.